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Ketorolac is a potent nonsteroidal anti-inflammatory drug. Recently, a novel ester of ketorolac, ketorolac
pentyl ester, was synthesized. When prepared in injectable oil, the new agent demonstrated a long duration
of action. Ketorolac pentyl ester was synthesized using a prodrug design by esterification of ketorolac, and
appeared to be a prodrug of ketorolac in vivo, which needed to be confirmed. The aim of the present study
was to establish the prodrug’s pharmacokinetics in vivo, and to confirm whether or not ketorolac pentyl ester
was a prodrug of ketorolac. Pharmacokinetic profiles of intravenous ketorolac and its pentyl ester on an
equal-molar basis in six rabbits were evaluated. A high-performance liquid chromatographic method was
used to determine the plasma concentrations of ketorolac and its pentyl ester. We found that the plasma
concentrations of ketorolac pentyl ester declined rapidly after injection and so did the conversion of
ketorolac pentyl ester to ketorolac. Also, the conversion of ketorolac was proved complete when compared
with intravenous ketorolac under an equi-molar basis. In conclusion, this in vivo pharmacokinetic study
confirmed that keterolac pentyl ester was a prodrug of keterolac.
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Most patients who experience moderate to severe pain
(e.g. postoperative pain, post-traumatic pain and burn
pain) often require analgesics in the first 3 days after injury
[1–6]. An analgesic with a long-lasting effect of 2–3 days
may be particularly valuable for these patients. Currently,
opioids and nonsteroidal anti-inflammatory drugs
(NSAIDs) are commonly used analgesics in these cases. To
date, several long-acting opioids have been developed
and/or clinically available (such as transdermal fentanyl
or buprenorphine patch, long-acting ester derivatives of
nalbuphine or buprenorphine) [1,2,7–9]. However, no
long-acting NSAID has been developed or has been
clinically available.
Among the NSAIDs, ketorolac is the most potent [3–6],
with an analgesic potency comparable to some opioids and
is an attractive alternative to opioids for the management of
moderate to severe pain. Ketorolac is commonly used in the
postoperative setting, in both hospital inpatients and
outpatients, and in patients in various pain states [3–6].
Ketorolac 10–30 mg intramuscular (IM) injection has similar
analgesic efficacies to those of morphine 6–12 mg and
pethidine 50–100 mg IM [3–6,10–12]. Although ketorolac
has a potent analgesic effect, its duration of action is
relatively short (4–6 hours following 10–30 mg IM).
Prolonging the duration of action would make ketorolac
more clinically valuable for treating long-lasting pain.
Recently, an ester of ketorolac, ketorolac pentyl ester
(Figure 1), was synthesized and evaluated [13,14]. When
prepared in an injectable oil as a depot formulation and
injected IM in rats, ketorolac pentyl ester was found to have
a long-lasting analgesic effect that was 7.8-fold longer
than the traditional saline dosage form of ketorolac,
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estimated to be 2–3 days following IM injection in humans
[14]. This promising result was deemed worth subsequent
evaluation.
In the depot formulation, ketorolac pentyl ester was
synthesized through a prodrug design with an esterification
method, and was suspected to be a prodrug of ketorolac in
vivo. This status had yet to be tested, and the aim of our
study was to carry out an in vivo pharmacokinetic analysis,
in order to test whether ketorolac pentyl ester was a prodrug
of ketorolac or not.
MATERIALS AND METHODS
Six male New Zealand white rabbits weighing between 2.6
and 3.1 kg were used. They were housed individually for at
least 1 week in a climate-controlled room, and maintained
at 21°C with approximately 50% relative humidity. Lighting
was on a 12-hour light/dark cycle (light on at 6:00 a.m.),
with food and water available ad libitum, except during the
time of testing. The protocol was approved by the animal
investigation committee of Chi-Mei Medical Center.
Ketorolac (tromethamine salt) was purchased from
Sigma (St Louis, MO, USA). Ketorolac pentyl ester
(Figure 1) was synthesized by using the method reported
previously [13]. In brief, it was obtained by inducing
ketorolac to react with the pentyl alcohol (Kanto Chemical,
Tokyo, Japan), in the presence of 4-dimethylaminopyridine
(Sigma, St Louis, MO, USA). Purity (> 99%) of the final
product was assured by elemental analysis, nuclear magnetic
resonance spectroscopy, and gas chromatography with mass
spectrum detector.
The pharmacokinetic profiles of ketorolac and its pentyl
ester in six rabbits were evaluated, using two studies. In
study 1, the pharmacokinetic profile of ketorolac following
intravenous (IV) injection of ketorolac 10 mg/kg (26.57
µmol/kg) was evaluated. In study 2, the pharmacokinetic
profiles of ketorolac and its pentyl ester following IV injection
of ketorolac pentyl ester 26.57 µmol/kg (8.65 mg/kg) were
evaluated. A cross-over design in six rabbits was used.
All six rabbits received one of the treatments (study 1 or 2),
randomly at week 1, and another at week 2. Following IV
medication, a 5-mL blood sample was obtained from the
artery of each rabbit’s ear at time zero and 1 mL at times 2,
3, 5, 10, 15, 30 minutes and 1, 2, 4, 6 and 8 hours.
In order to determine the plasma concentrations of
ketorolac and its pentyl ester, a method of high-performance
liquid chromatography (HPLC) was used. The HPLC system
consisted of a pump (Series 200 LC Pump, Perkin-Elmer,
CT, USA), an automatic sampler (Series 200 Autosampler,
Perkin-Elmer, CT, USA), a programmable ultraviolet
detector (at 314 nm, Series 200, Perkin-Elmer, CT, USA),
and an integrator (Chromatography Data Station,
Turbochrom Workstation, Perkin-Elmer, CT, USA). A
reverse-phase column (Nucleosil C18, No. 720014.46,
250 × 4.6 mm, 5 µm particle size, Macherey-Nagel GmbH,
Düren, Germany) was also used. The mobile phase of the
HPLC system was 50 mM sodium acetate buffer (pH = 6) in
acetonitrile (25:75, v/v). The flow-rate of the pumping
system was set to be 1 mL/min at 25°C, which yielded a
back-pressure of about 2,500 psi. In the HPLC method, the
calibration curves were linear with correlation coefficients
of around 0.999 for both ketorolac and its pentyl ester. The
extraction recoveries of ketorolac and its pentyl ester were
around 92–95%. The low quantitation limits of ketorolac
and its pentyl ester were 10.0 and 15.0 ng/mL, respectively.
In order to prevent the enzymatic hydrolysis of ketorolac
pentyl ester in the blood, the blood sample (1 mL) obtained
from rabbits was added immediately to a 10-mL capacity
polypropylene (PP) tube, which contained 4 mL of chilled
ethyl acetate for quenching the hydrolysis reaction. Ethyl
acetate was also used as an extraction solvent. After a 10-
second shaking, the analytes were then put on a rotary shaker
for 30 minutes at 100 rpm for extraction. After centrifugation
at 1,880 gm (centrifugal force) for 20 minutes, the PP tubes
were put into a freezer (–20°C) for 1 hour. After the lower
layer (blood) was frozen, the organic layer was poured into
another 5-mL PP tube and evaporated to dryness under a
Figure 1. Chemical structure of
ketorolac and its pentyl ester.
Ketorolac Ketorolac pentyl ester
Pharmacokinetics of ketorolac pentyl ester
Kaohsiung J Med Sci August 2005 • Vol 21 • No 8 367
stream of filtered dry air. The samples were then reconstituted
by 250 µL of the mobile phase of the HPLC system. Aliquots
of 200 µL were injected into the HPLC system.
The plasma concentration-time profiles of ketorolac
and its pentyl ester were fitted by using the computer
program PCNONLIN (version 3.0, Statistical consultants)
[15]. Akaike information criteria, weighted residual sum
of squares, and residual plots were used to judge the
goodness-of-fit of the model to data [16]. A CSTRIP
computer program was used to obtain the initial parameter
estimations, which were required for nonlinear regression
analysis by the computer program PCNONLIN [15].
Pharmacokinetic parameters were calculated by standard
formulae [15,16]. We compared the area under curve (AUC)
of ketorolac that converted from ketorolac pentyl ester
with that obtained from direct IV injection of ketorolac.
The bioequivalence of these two AUCs was tested by using
two one-sided t tests. A p value of less than 0.05 was
considered significant.
RESULTS
The pharmacokinetic profiles of ketorolac and its pentyl ester
following IV administration of either ketorolac or its pentyl
ester are demonstrated in Figure 2 and the Table. Following
IV administration of ketorolac, the plasma concentrations of
ketorolac were successfully fitted to a two-compartment
model with one distribution phase and one elimination
phase (Figure 2 and the Table). Following IV administration
of ketorolac pentyl ester, the plasma concentrations of
ketorolac pentyl ester declined rapidly and were successfully
fitted to a two-compartment model with one distribution
phase and one elimination phase. Meanwhile, the conversion
of ketorolac pentyl ester to ketorolac occurred rapidly,
following the administration of its pentyl ester and the
plasma concentrations of ketorolac, which were also fitted to
a two-compartment absorption model (Figure 2 and the
Table). After comparing the AUC data of ketorolac following
IV ketorolac with those following IV ketorolac pentyl ester,
we found that there was no significant difference between
these two AUC data (Table). This meant that, following IV
administration, ketorolac pentyl ester, which was totally
converted to ketorolac, was a prodrug of ketorolac.
DISCUSSION
Depot formulation with prodrug design is one of the
methods used to increase the duration of a drug’s action
[17–19]. For example, several prodrugs such as haloperidol
decanoate, fluphenazine enanthate, estradiol cypionate,
and testosterone undecanoate, are synthesized from their
active drugs, namely haloperidol, fluphenazine, estradiol,
and testosterone, by esterification [19,20]. Esterification of
drugs with various fatty acids results in an increase in their
Figure 2. Plasma concentration-
time profiles of ketorolac and its
pentyl ester, following intravenous
ketorolac or its pentyl ester in 6
rabbits. Data were mean ± SE and
were fitted by a computer program
of PCNONLIN.
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lipophilicity [17–19]. When these prodrug-type esters are
dissolved in injectable oils and given IM, long durations of
actions will be obtained due to a slow-release characteristic
of these esters from the oily vehicles [19]. Once released
from the vehicles within the muscle, esters will be
hydrolyzed by esterases and become the active drugs [17–
21]. Esterases exist in many tissues and organs, such as in
the blood, brain, liver, lung, etc.
In a previous study, ketorolac pentyl ester was
synthesized and formulated into the injectable sesame oil as
the oil solution. Following IM injection in rats, a long-acting
analgesic effect was found [14]. Since long-acting analgesic
is particularly valuable for patients with long-lasting pain,
the development of a long-acting NSAID is worth pursuing.
In this novel depot, ketorolac pentyl ester was synthesized
through a prodrug design with an esterification method
[14]. It was expected to be a prodrug of ketorolac in vivo.
However, this was not tested before.
Following IV administration, the plasma concentrations
of ketorolac pentyl ester were successfully fitted to a two-
compartment open model with one distribution phase and
one elimination phase. The distribution and elimination
half-lives were 1.08 ±  0.13 and 13.2 ±  1.2 minutes,
respectively (Table). The very short elimination half-life
indicated that ketorolac pentyl ester was eliminated quickly
from the plasma following IV administration. We also
found that the formation of ketorolac from ketorolac pentyl
ester occurred rapidly. A high plasma concentration of
ketorolac could be detected even at 2 minutes following the
administration of ketorolac pentyl ester (Figure 2). The
plasma concentrations of ketorolac-converted were
successfully fitted to a two-compartment absorption model
with an absorption half-life of 0.487 ± 0.002 minutes (Table).
The extremely short half-life further indicated that ketorolac
pentyl ester was rapidly converted to ketorolac following
IV administration. Under an equi-molar basis of drug
administration, we further found that the AUC of ketorolac-
converted was equal to that of ketorolac by direct IV
administration. This meant that ketorolac pentyl ester, which
was totally converted to ketorolac, was a prodrug of ketorolac.
In conclusion, an in vivo pharmacokinetic study of
ketorolac and its pentyl ester in rabbits was carried out.
Following IV administration, ketorolac pentyl ester, which
was rapidly and totally converted to ketorolac, was a prodrug
of ketorolac.
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